Recombinant Retroviral Vector Non-Integration Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genetic delivery methods using viral vectors face challenges such as undesired mitogenic effects, integration into host cell genomes, and immune responses, while RNA-based vehicles are complex and prone to degradation, necessitating a safer and more efficient delivery method for therapeutics.
Innovation Solution
A recombinant retroviral vector with a deleted integrase and a nucleic acid sequence encoding a payload, specifically designed to prevent integration into host cell genomes and enhance immune response through antigen delivery, utilizing modifications like codon optimization and amino acid mutations to improve expression and targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If retroviral vectors are used for delivering therapeutics, then delivery efficiency is improved, but integration into host cell genomes occurs causing mitogenic effects and cancer risk
Solution Approach 1:
The patent removes the integrase enzyme from the retroviral vector through deletion of the integrase coding sequence. This extraction of the harmful integration function allows the vector to maintain efficient delivery capabilities while eliminating the ability to integrate into host genomes, thereby preventing mitogenic effects and cancer risk.
2Object-affected harmful factors
If RNA-based vehicles are used for delivering genetic material, then integration risk is reduced, but complexity and labor requirements increase
Solution Approach 1:
The patent creates a modified version of the retroviral vector that copies the efficient delivery mechanisms of RNA-based systems while avoiding their limitations. By using a DNA-based retroviral vector without integrase, it replicates the non-integrating behavior of RNA vectors but maintains the simplicity and stability of DNA-based construction and delivery.
3Object-affected harmful factors
If RNA-based vehicles are used for delivering therapeutics, then integration risk is reduced, but stability and half-life decrease
Solution Approach 1:
The patent creates a composite therapeutic system combining a retroviral vector structure with deleted integrase and a payload encoding sequence. This composite approach leverages the stability and longevity of DNA-based vectors while the deleted integrase ensures non-integration behavior similar to RNA vectors, achieving both safety and durability.
4Object-affected harmful factors
If non-viral DNA vehicles are used for delivering therapeutics, then integration risk is reduced, but transport efficiency and targeting capability decrease
Solution Approach 1:
The patent applies local quality modification by specifically deleting only the integrase coding sequence from the retroviral vector while preserving other functional elements such as envelope proteins for targeting and structural genes for efficient delivery. This localized modification maintains transport efficiency and targeting capability while eliminating integration risk.
Data Source
AI summary
Described herein are compositions comprising recombinant viral vectors, e.g., recombinant retroviral vectors, for delivering a therapeutic or a vaccine. The recombinant retroviral vectors described herein are modified for safer application of therapeutic or vaccine delivery. Also described herein are methods for using the compositions comprising recombinant viral vectors for delivering a therapeutic or a vaccine.